Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04763460
Other study ID # IRBnet#: 1706252
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 1, 2021
Est. completion date April 1, 2025

Study information

Verified date September 2021
Source Allina Health System
Contact Christopher D Brown
Phone 651-241-2806
Email christopher.brown2@allina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cardiac resynchronization therapy (CRT), or atrial-synchronized biventricular (BiV) pacing, is an FDA-approved device therapy option for heart failure (HF) patients with reduced left ventricular ejection fraction and electrical dyssynchrony. A traditional CRT device has pacing leads implanted within the right atrium (RA), the right ventricle (RV), and within a coronary vein overlying the lateral or posterior left ventricle (LV). Within the past decade, various multi-center randomized controlled trials have reported improved quality of life, aerobic exercise capacity, LV systolic function and structure, as well as decreased hospitalization rates and mortality among patients with HF. Despite improvements in CRT technology with multipoint pacing, quadripolar leads, and adaptive pacing algorithms, approximately 30% of patients do not clinically benefit and are considered non-responders. This study looks to optimize CRT device programming in patients considered non-responders to CRTusing information obtained from standard ECG machines, and to assess acute and chronic effects of CRT optimization using cardiac magnetic resonance imaging (CMR).


Description:

This is a prospective, randomized study designed to evaluate if CRT device optimization, guided by electrocardiography, improves cardiac function and clinical outcomes among patients considered non-responders to CRT. All patients will have electrocardiographic assessment of electrical dyssynchrony at a range of device settings using standard ECG machines. All patients will then have a baseline CMR study at baseline CRT programming, underlying rhythm, and optimal settings derived from the electrocardiographic assessment to assess acute effects of CRT optimization on mechanical synchrony, LV regional wall motion, and LV structure/ function. To assess chronic effects of CRT optimization, patients will be randomized in a 1:1 ratio after baseline CMR to either the active comparator arm (baseline CRT programming), or the experimental arm (CRT device programmed to optimal settings derived from the electrocardiographic assessment). Patients will be blinded to randomization. After 6 month, all patients will return for follow up CMR study to assess chronic effects. After follow up CMR imaging, the active comparator group will crossover to the experimental group. After 12 months, all patients will return for follow up echocardiogram to further evaluate the chronic effects of CRT optimization.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date April 1, 2025
Est. primary completion date April 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: 1. Currently on standard medical therapy 2. CRT device in place for > 4 months 3. Non-responder (ejection fraction improvement with CRT < 5%) or incomplete responder (ejection fraction < 40%) 4. Suboptimal electrical wavefront fusion at current CRT programming as observed on 12-lead ECG 5. Left bundle branch block, interventricular conduction delay or right ventricular paced underlying QRS complex 6. Age > 18 years Exclusion Criteria: 1. Decompensated heart failure 2. Right bundle branch block 3. Pregnancy or lactation 4. History of severe allergic reactions to ECG gels, electrode adhesives, and/or cardiac magnetic resonance contrast (e.g. gadolinium) 5. Implantation of pacing lead in the his bundle or left bundle branch 6. Frequent ventricular ectopy as defined as >10% premature ventricular contraction burden by either device interrogation or Holter monitor, or sustained ventricular tachycardia/ventricular fibrillation 7. Uncontrolled atrial fibrillation (HR > 100 bpm) 8. Patient is enrolled in concurrent research study that would potentially confound the results of this study (noting: co-enrollment acceptable if patient is enrolled in registry study)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Programming of CRT device settings
Reprogramming of CRT device to maximize the benefit derived from the electrocardiographic assessment.

Locations

Country Name City State
United States Minneapolis Heart Institute - Abbott Northwestern Hospital (MHI West) Minneapolis Minnesota
United States United Heart & Vascular Clinic - Nasseff Specialty Center (MHI East) Saint Paul Minnesota

Sponsors (2)

Lead Sponsor Collaborator
Allina Health System Minneapolis Heart Institute Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Correlation in electrical dyssynchrony and left ventricular function in study population Changes in electrical dyssynchrony, measured by electrocardiography, and correlation to change in left ventricular function, measured by cardiac magnetic resonance and echocardiographic imaging, in all patients. Baseline to 12 months
Primary Acute changes in left ventricular mechanical synchrony in study population Acute changes, measured by cardiac magnetic resonance imaging, in left ventricular mechanical synchrony at underlying rhythm, baseline CRT programming, and optimal programming derived from electrocardiographic assessment in all patients. During Baseline Assessment
Primary Acute changes in left ventricular regional wall motion in study population Acute changes, measured by cardiac magnetic resonance imaging, in left ventricular wall motion at underlying rhythm, baseline CRT programming, and optimal programming derived from electrocardiographic assessment in all patients. During Baseline Assessment
Primary Acute changes in left ventricular end-diastolic volume in study population Acute changes, measured by cardiac magnetic resonance imaging, in left ventricular end-diastolic volume at underlying rhythm, baseline CRT programming, and optimal programming derived from electrocardiographic assessment in all patients. During Baseline Assessment
Primary Acute changes in left ventricular end-systolic volume in study population Acute changes, measured by cardiac magnetic resonance imaging, in left ventricular end-systolic volume at underlying rhythm, baseline CRT programming, and optimal programming derived from electrocardiographic assessment in all patients. During Baseline Assessment
Primary Chronic changes in left ventricular mechanical synchrony Chronic changes, measured by cardiac magnetic resonance imaging and echocardiography, in left ventricular mechanical synchrony between the experimental and active comparator group. Baseline to 12 months
Primary Chronic changes in left ventricular regional wall motion Chronic changes, measured by cardiac magnetic resonance imaging and echocardiography, in left ventricular regional wall motion between the experimental and active comparator group. Baseline to 12 months
Primary Chronic changes in left ventricular end-diastolic volume Chronic changes, measured by cardiac magnetic resonance imaging and echocardiography, in left ventricular end-diastolic volume between the experimental and active comparator group. Baseline to 12 months
Primary Chronic changes in left ventricular end-systolic volume Chronic changes, measured by cardiac magnetic resonance and echocardiographic imaging, in left ventricular end-systolic volume between the experimental and active comparator group. Baseline to 12 months
Secondary Change in 6 Minute Hall Walk (6MHW) Comparison between experimental arm and active comparator arm in 6MHW Baseline to 12 months
Secondary Change in Kansis City Cardiomyopathy Questionnaire (KCCQ) Comparison between experimental arm and active comparator arm in KCCQ. Scores are scaled 0-100. Higher scores indicate better outcomes. Baseline to 12 months
See also
  Status Clinical Trial Phase
Withdrawn NCT03227393 - The Effect of Yoga on Cardiac Sympathetic Innervation Evaluated by I-123 mIBG N/A
Recruiting NCT04528004 - Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure Early Phase 1
Recruiting NCT04703842 - Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction Phase 1/Phase 2
Recruiting NCT04522609 - Electrostimulation of Skeletal Muscles in Patients Listed for a Heart Transplant N/A
Completed NCT05475028 - Network Medicine Approaches to Classify Heart Failure With PReserved Ejection Fraction by Signatures of DNA Methylation and Point-of-carE Risk calculaTors (PRESMET)
Not yet recruiting NCT06240403 - Digoxin and Senolysis in Heart Failure and Diabetes Mellitus Phase 2
Not yet recruiting NCT05988749 - Digital Remote Home Monitoring for Heart Failure N/A
Recruiting NCT04950218 - The Psoriasis Echo Study
Suspended NCT04701112 - Acute Hemodynamic Effects of Pacing the His Bundle in Heart Failure N/A
Completed NCT03305692 - ECG Belt vs. Echocardiographic Optimization of CRT N/A
Recruiting NCT05933083 - MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation N/A
Enrolling by invitation NCT03903107 - The Fluoroless-CSP Trial Using Electroanatomic Mapping N/A
Withdrawn NCT04872959 - TRANSFORM Heart Failure With Reduced Ejection Fraction N/A
Completed NCT02920918 - Treatment of Diabetes in Patients With Systolic Heart Failure Phase 4
Completed NCT02334891 - Kyoto Congestive Heart Failure Study
Recruiting NCT03553303 - Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin Phase 4
Recruiting NCT04083690 - Multi-lead ECG to Effectively Optimize Resynchronization Devices: New CRT Recipients N/A
Recruiting NCT03830957 - Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker N/A
Recruiting NCT06121323 - Physiological Effects of Lactate in Individuals With Chronic Heart Failure N/A
Completed NCT03351283 - Effect of Sodium Intake on Brain Natriuretic Peptide Levels in Patients With Heart Failure N/A